Proteomic analysis for elucidation of individual differences in chemotherapeutic response and for biomarker development
| Project/Area Number |
20390049
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
TANIGAWARA Yusuke Keio University, 医学部, 教授 (30179832)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
WATANABE Mitsuhiro 慶應義塾大学, 医学部, 准教授 (10450842)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥19,370,000 (Direct Cost: ¥14,900,000、Indirect Cost: ¥4,470,000)
Fiscal Year 2010: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2009: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
Fiscal Year 2008: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
|---|
| Keywords | 個別化医療 / 抗癌剤 / 薬剤反応性 / バイオマーカー / プロテオーム / SELDI-TOF MS / オキサリプラチン / イリノテカン / 個人差 |
|---|
| Research Abstract |
We applied proteomic approach to elucidate individual differences in chemotherapeutic response of human colorectal cancer cells and to develop protein biomarkers for predicting chemosensitivity. We have identified the protein S100A10 whose expression well correlated with sensitivity to oxaliplatin, and our findings suggested this protein a potential biomarker in clinical setting. Furthermore, we have also found several proteins as potential biomarkers to predict sensitivity to anticancer drugs such as 5-fluorouracil and active metabolite of irinotecan.
|
Report
(4 results)
Research Products
(56 results)
